Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C

References

• Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl. 2004;10(7):850–858.
   PubMed Web of Science ®Google Scholar
• Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49(4):613–624.
   PubMed Web of Science ®Google Scholar
• Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007;46(2):206–212.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-SALT Part A). The International Liver Congress, EASL; 2015; Vienna, Austria.
   Google Scholar
• Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–1097.
   PubMed Web of Science ®Google Scholar
• Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–1545.
   PubMed Web of Science ®Google Scholar
• Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564–572.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gane E, Peng CY, et al. Efficacy and safety of grazoprevir/elbasvir ± RBV for 12 or 16 weeks in patients with HCV G1, G4 or G6 infection who previously failed Peginterferon/RBV: C-EDGE treatment experienced. The International Liver Congress, EASL; 2015; Vienna, Austria.
   Google Scholar
• Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8(12):1930–1940.
   PubMed Web of Science ®Google Scholar
• Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56(8):4161–4167.
   PubMed Web of Science ®Google Scholar
• Zuckerman MJ, Menzies IS, Ho H, et al. Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes. Dig Dis Sci. 2004;49(4):621–626.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161.
   PubMed Web of Science ®Google Scholar
• Therapeutics J. Olysio (simeprevir) full prescribing information [Internet]. 2016 [cited 2016 Mar 3]. Available from: https://www.olysio.com/shared/product/olysio/prescribing-information.pdf
   Google Scholar
• Abbvie. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) full prescribing information [Internet]. 2016 [cited 2016 Mar 3]. Available from: http://www.rxabbvie.com/pdf/viekirapak_pi.pdf
   Google Scholar
• Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–569.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–413.
   PubMed Web of Science ®Google Scholar
• Mira JA, Rivero-Juarez A, Lopez-Cortes LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56(11):1646–1653.
   PubMed Web of Science ®Google Scholar
• Grebely J, Oser M, Taylor LE, et al. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207 Suppl 1:S19–25.
   Google Scholar
• Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138(3):197–207.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14(10):697–703.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Cacoub P, et al. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16(12):1815–1827.
   PubMed Web of Science ®Google Scholar
• Sciences G. Sovaldi (sofosbuvir) full prescribing information [Internet]. 2016 [cited 2016 Mar 3]. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
   Google Scholar
• Costilla V, Mathur N, Gutierrez JA. Mechanisms of virologic failure with direct-acting antivirals in hepatitis C and strategies for retreatment. Clin Liver Dis. 2015;19(4):641–656.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.
   PubMed Web of Science ®Google Scholar
• Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–659.
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628.
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. The International Liver Congress 2015, EASL; 2015; Vienna, Asutria.
   Google Scholar